
Biohaven Stock Climbs on Favorable Trade Secret Ruling and Pipeline Outlook
Shares of the biopharmaceutical company gained after a federal jury affirmed its licensed rights to a key drug platform and as investors anticipate key clinical trial data in the second half of the year.







